CN114428138B - 基于磁性固相萃取的儿茶酚胺及其代谢物的液相色谱串联质谱检测方法 - Google Patents
基于磁性固相萃取的儿茶酚胺及其代谢物的液相色谱串联质谱检测方法 Download PDFInfo
- Publication number
- CN114428138B CN114428138B CN202210227411.9A CN202210227411A CN114428138B CN 114428138 B CN114428138 B CN 114428138B CN 202210227411 A CN202210227411 A CN 202210227411A CN 114428138 B CN114428138 B CN 114428138B
- Authority
- CN
- China
- Prior art keywords
- phase extraction
- solid phase
- magnetic solid
- filler
- transferring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002414 normal-phase solid-phase extraction Methods 0.000 title claims abstract description 92
- 238000001514 detection method Methods 0.000 title claims abstract description 57
- 150000003943 catecholamines Chemical class 0.000 title claims abstract description 56
- 239000002207 metabolite Substances 0.000 title claims abstract description 44
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 40
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 36
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims abstract description 24
- 229960002748 norepinephrine Drugs 0.000 claims abstract description 24
- 229960003638 dopamine Drugs 0.000 claims abstract description 18
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 claims abstract description 15
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims abstract description 13
- 229930182837 (R)-adrenaline Natural products 0.000 claims abstract description 11
- 229960005139 epinephrine Drugs 0.000 claims abstract description 11
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims abstract description 5
- 229960001802 phenylephrine Drugs 0.000 claims abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 108
- 239000000945 filler Substances 0.000 claims description 73
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 54
- 238000002156 mixing Methods 0.000 claims description 37
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 27
- 235000019253 formic acid Nutrition 0.000 claims description 27
- 239000011259 mixed solution Substances 0.000 claims description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 239000012071 phase Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000012086 standard solution Substances 0.000 claims description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- 150000002500 ions Chemical class 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 4
- 239000005695 Ammonium acetate Substances 0.000 claims description 4
- 235000019257 ammonium acetate Nutrition 0.000 claims description 4
- 229940043376 ammonium acetate Drugs 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- -1 BEH Amide Chemical class 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003643 water by type Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 6
- 238000012546 transfer Methods 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 35
- 239000000047 product Substances 0.000 description 27
- 210000002381 plasma Anatomy 0.000 description 9
- 238000010606 normalization Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- 239000012491 analyte Substances 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 239000013076 target substance Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000007312 paraganglioma Diseases 0.000 description 3
- 208000028591 pheochromocytoma Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960002795 dl- norepinephrine Drugs 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- NHWAXWGUTHDCEF-FIBGUPNXSA-N trideuterio-lambda3-chlorane Chemical compound Cl([2H])([2H])[2H] NHWAXWGUTHDCEF-FIBGUPNXSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- SONNWYBIRXJNDC-UHFFFAOYSA-N 3-[1-Hydroxy-2-(methylamino)ethyl]phenol Chemical compound CNCC(O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-UHFFFAOYSA-N 0.000 description 1
- CTENFNNZBMHDDG-URZLSVTISA-N 4-(2-amino-1,1,2,2-tetradeuterioethyl)benzene-1,2-diol;hydrochloride Chemical compound Cl.[2H]C([2H])(N)C([2H])([2H])C1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-URZLSVTISA-N 0.000 description 1
- FQTFHMSZCSUVEU-UHFFFAOYSA-N 4-(2-amino-1-hydroxyethyl)benzene-1,2-diol;hydron;chloride Chemical compound Cl.NCC(O)C1=CC=C(O)C(O)=C1 FQTFHMSZCSUVEU-UHFFFAOYSA-N 0.000 description 1
- DIVQKHQLANKJQO-KJGQCWIOSA-N 4-[2,2-dideuterio-2-(dideuterioamino)ethyl]-2-methoxyphenol Chemical compound [2H]N([2H])C([2H])([2H])Cc1ccc(O)c(OC)c1 DIVQKHQLANKJQO-KJGQCWIOSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 208000026564 adrenal medullary hyperplasia Diseases 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 150000002871 norepinephrines Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
Q1 | Q3 | Dwell time | ID | DP | EP | CE |
184.2 | 166 | 15 | E-1 | 36 | 7 | 12 |
190.2 | 172.1 | 15 | E-d6 | 38 | 6 | 13 |
170.3 | 152.1 | 15 | NE-1 | 36 | 7 | 11 |
176.1 | 158.1 | 15 | NE-d6 | 55 | 7 | 9 |
198.1 | 180.1 | 15 | MN-1 | 35 | 7 | 11 |
183.2 | 151.2 | 15 | MN-d3 | 80 | 8 | 24 |
184.1 | 166.1 | 15 | NMN-1 | 35 | 6 | 12 |
187.1 | 169.1 | 15 | NMN-d3 | 35 | 6 | 12 |
168.1 | 91 | 15 | 3-MT-1 | 44 | 7 | 32 |
172 | 155.1 | 15 | 3-MT-d4 | 43 | 6 | 14 |
154.1 | 91.1 | 15 | DA-1 | 52 | 7 | 33 |
158.1 | 141 | 15 | DA-d4 | 20 | 10 | 30 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210227411.9A CN114428138B (zh) | 2022-03-08 | 2022-03-08 | 基于磁性固相萃取的儿茶酚胺及其代谢物的液相色谱串联质谱检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210227411.9A CN114428138B (zh) | 2022-03-08 | 2022-03-08 | 基于磁性固相萃取的儿茶酚胺及其代谢物的液相色谱串联质谱检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114428138A CN114428138A (zh) | 2022-05-03 |
CN114428138B true CN114428138B (zh) | 2024-05-10 |
Family
ID=81313394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210227411.9A Active CN114428138B (zh) | 2022-03-08 | 2022-03-08 | 基于磁性固相萃取的儿茶酚胺及其代谢物的液相色谱串联质谱检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114428138B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116223690B (zh) * | 2023-04-18 | 2024-02-27 | 苏州颐坤生物科技有限公司 | 一种从血浆中提取并检测6项儿茶酚胺及其代谢物的lc-ms/ms试剂盒 |
CN116448923A (zh) * | 2023-06-20 | 2023-07-18 | 中国医学科学院北京协和医院 | 提取和检测类固醇激素及儿茶酚胺代谢物的方法和试剂盒 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017077401A1 (en) * | 2015-11-02 | 2017-05-11 | Pharmasan Labs, Inc. | Method for the ultra-sensitive determination of catecholamines and their metabolites |
CN108452784A (zh) * | 2018-04-04 | 2018-08-28 | 广西民族大学 | 儿茶酚胺固相萃取功能复合材料及其制备方法和应用 |
CN111175394A (zh) * | 2020-01-08 | 2020-05-19 | 中国医学科学院阜外医院 | 一种液相色谱串联质谱检测血浆儿茶酚胺及其代谢物的方法 |
CN112505168A (zh) * | 2020-10-22 | 2021-03-16 | 青岛惠安康生物工程有限公司 | 一种儿茶酚胺的lc-ms/ms检测方法及预处理试剂盒 |
CN113720939A (zh) * | 2021-09-02 | 2021-11-30 | 北京梅斯质谱生物科技有限责任公司 | 一种磁珠法自动化定量测定血浆中6种儿茶酚胺的试剂盒 |
-
2022
- 2022-03-08 CN CN202210227411.9A patent/CN114428138B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017077401A1 (en) * | 2015-11-02 | 2017-05-11 | Pharmasan Labs, Inc. | Method for the ultra-sensitive determination of catecholamines and their metabolites |
CN108452784A (zh) * | 2018-04-04 | 2018-08-28 | 广西民族大学 | 儿茶酚胺固相萃取功能复合材料及其制备方法和应用 |
CN111175394A (zh) * | 2020-01-08 | 2020-05-19 | 中国医学科学院阜外医院 | 一种液相色谱串联质谱检测血浆儿茶酚胺及其代谢物的方法 |
CN112505168A (zh) * | 2020-10-22 | 2021-03-16 | 青岛惠安康生物工程有限公司 | 一种儿茶酚胺的lc-ms/ms检测方法及预处理试剂盒 |
CN113720939A (zh) * | 2021-09-02 | 2021-11-30 | 北京梅斯质谱生物科技有限责任公司 | 一种磁珠法自动化定量测定血浆中6种儿茶酚胺的试剂盒 |
Non-Patent Citations (1)
Title |
---|
液相色谱-串联质谱法测定血浆中甲氧基肾上腺素和甲氧基去甲肾上腺素;李艳;许舒欣;刘海培;张远清;胡玮;李小强;程文播;;分析科学学报;20200620(第03期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN114428138A (zh) | 2022-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zheng et al. | A sensitive, high-throughput LC-MS/MS method for measuring catecholamines in low volume serum | |
CN111175394B (zh) | 一种液相色谱串联质谱检测血浆儿茶酚胺及其代谢物的方法 | |
CN114428138B (zh) | 基于磁性固相萃取的儿茶酚胺及其代谢物的液相色谱串联质谱检测方法 | |
CN111812216A (zh) | 一种检测血清中抗癫痫药物浓度的方法 | |
US20100178663A1 (en) | Apparatus And Methods For The Detection Of Plasma Metanephrines | |
Gałęzowska et al. | Determination of amino acids in human biological fluids by high-performance liquid chromatography: Critical review | |
Li et al. | Development and validation of a semi-automated method for L-dopa and dopamine in rat plasma using electrospray LC/MS/MS | |
CN113933423B (zh) | 一种测定人血清中23种精神类药物及代谢物的检测方法 | |
CN112630311B (zh) | 用于检测情感障碍的代谢标记物和试剂盒及使用方法 | |
CN111537648A (zh) | 一种超高效液相色谱串联质谱技术检测血清中抗结核病药物的试剂盒 | |
CN111398450A (zh) | 超高效液相色谱串联质谱技术检测尿液中8种儿茶酚胺及其代谢物的试剂盒 | |
CN111766311A (zh) | 一种超高效液相色谱串联质谱技术检测血清中抗结核病药物的方法 | |
CN111812218A (zh) | 一种同时检测血清中多种抗精神病药物浓度的方法 | |
Jeong et al. | Amino acid analysis of dried blood spots for diagnosis of phenylketonuria using capillary electrophoresis-mass spectrometry equipped with a sheathless electrospray ionization interface | |
CN113588804A (zh) | 一种检测血清中5-羟色胺和褪黑素浓度的试剂盒 | |
CN111458417B (zh) | 联合检测待测样品中多种抗生素的方法及试剂盒 | |
Magiera et al. | Simultaneous chiral separation and determination of carvedilol and 5′-hydroxyphenyl carvedilol enantiomers from human urine by high performance liquid chromatography coupled with fluorescent detection | |
CN111912921A (zh) | 一种超高效液相色谱串联质谱技术检测血浆中3种脂质的方法 | |
Giordano et al. | Quantification of underivatized amino acids on dry blood spot, plasma, and urine by HPLC-ESI-MS/MS | |
CN111896646A (zh) | 一种超高效液相色谱串联质谱技术检测血浆中3种脂质的试剂盒 | |
CN111896643A (zh) | 一种人血浆中儿茶酚胺的液相色谱串联质谱检测方法 | |
CN116297993A (zh) | 高效液相色谱串联质谱测定红细胞中叶酸及其代谢物的试剂盒 | |
CN114624361A (zh) | 同时测定人血浆中别嘌醇和氧别嘌醇浓度的方法 | |
CN114062531A (zh) | 一种类风湿关节炎早期滑膜液诊断试剂盒及其应用 | |
CN111665307A (zh) | 一种检测血清中多粘菌素b1和多粘菌素b2浓度的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant after: Tianjin Guoke Medical Technology Development Co.,Ltd. Address before: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant before: TIANJIN GUOKE YIGONG TECHNOLOGY DEVELOPMENT Co.,Ltd. Country or region before: China |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240325 Address after: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant after: Tianjin Guoke Medical Technology Development Co.,Ltd. Country or region after: China Applicant after: Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Address before: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant before: Tianjin Guoke Medical Technology Development Co.,Ltd. Country or region before: China |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |